Routine pharmacogenetic testing in clinical practice: Dream or reality?

Pharmacogenomics

Volumn 8, Issue 10, 2007, Pages 1449-1459

  Grossman, Iris ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

CYP 450; Drug metabolizing enzymes; Evidence based medicine; Personalized medicine; Pharmacogenetics; Prospective study

Indexed keywords

ABACAVIR; ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E; ATYPICAL ANTIPSYCHOTIC AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; FLUOXETINE; GLUCURONOSYLTRANSFERASE 1A1; HLA B ANTIGEN; IRINOTECAN; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENYTOIN; PLACEBO; QUETIAPINE; RISPERIDONE; ROSIGLITAZONE; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN HYDROXYLASE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN; ZIPRASIDONE;

ALZHEIMER DISEASE; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TRANSFORMATION; DRUG UTILIZATION; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR DEPRESSION; NEUTROPENIA; PATIENT COMPLIANCE; PHARMACOGENETICS; RECTUM CANCER; REIMBURSEMENT; REPRODUCIBILITY; REVIEW; RISK REDUCTION; STANDARDIZATION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VALIDITY;

CLINICAL TRIALS AS TOPIC; DIAGNOSTIC TESTS, ROUTINE; HUMANS; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAFETY; SEROTONIN UPTAKE INHIBITORS;

EID: 36448955702     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.10.1449     Document Type: Review

References (65)

1. Lertola J: Deciphering the code and what might come from it. Time 68-69 (1999).
2. Roses AD: Pharmacogenetics. Hum. Mol. Genet. 10(20), 2261-2267 (2001).
3. McLeod HL, Siva C: The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3(1), 89-98 (2002).
4. Penny MA, McHale D: Pharmacogenomics and the drug discovery pipeline: when should it be implemented? Am. J. Pharmacogenomics 5(1), 53-62 (2005).
5. Yan L, Beckman RA: Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques 39(4), 565-568 (2005).
6. Muss HB, Thor AD, Berry DA et al.: C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330(18), 1260-1266 (1994).
7. US FDA: FDA releases final guidance for pharmacogenomic data. Pharmacogenomics 6(3), 209 (2005).
8. Wu X, Spitz MR, Amos CI et al.: Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res. 66(12), 5993-5996 (2006).
9. Vesell ES: Pharmacogenetic perspectives gained from twin and family studies. Pharmacol. Ther. 41(3), 535-552 (1989).
10. Nebert DW: Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants. Clin. Chem. Lab Med. 38(9), 857-861 (2000).
11. Hall IP: Pharmacogenetics of asthma. Chest 130(6), 1873-1878 (2006).
12. Mialet-Perez J, Liggett SB: Pharmacogenetics of β1 -adrenergic receptors in heart failure and hypertension. Arch. Mal Coeur Vaiss. 99(6), 616-620 (2006).
13. Tate SK, Depondt C, Sisodiya SM et al.: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl. Acad. Sci. USA 102(15), 5507-5512 (2005).
14. Grossman I, Liu Y, Walley N et al.: Pharmacogenetic analysis of antipsychotics: comprehensive analysis of pharmacokinetic variants. The American Society of Human Genetics, 56th annual meeting, New Orleans, Louisiana. (2006).
15. de Leon J, Susce MT, Murray-Carmichael E: The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol. Diagn. Ther. 10(3), 135-151 (2006).
16. de Leon J: AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert. Rev. Mol. Diagn. 6(3), 277-286 (2006).
17. Kirchheiner J, Nickchen K, Bauer M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5), 442-473 (2004).
18. de Leon J, Armstrong SC, Cozza KL: The dosing of atypical antipsychotics: Psychosomatics. 46(3), 262-273 (2005).
19. Liu CY, Chiu NY, Wu CK, Yuan LM, Hsiao MC, Liao O: Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. Int. Clin. Psychopharmacol. 18(1), 49-51 (2003).
20. Spina E, de Leon J: Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxicol. 100(1), 4-22 (2007).
21. Albers LJ, Ozdemir V: Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr. Med. Chem. 11(3), 297-312 (2004).
22. Darby JK, Pasta DJ, Elfand L, Dabirt L, Clark L. Herbert J: Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin. Psychopharmacol. 17(6), 478-484 (1997).
23. Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Pscyhiatry 12(8), 707-747 (2007).
24. Lieberman JA: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J. Clin. Psychiatry. 68(2), e04 (2007).
25. Stroup TS, McEvoy JP, Swartz MS et al.: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 29(1), 15-31 (2003).
26. Brosen K: Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 59(1), 5-12 (2004).
27. Ingelman-Sundberg M, Oscarson M, McLellan RA: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment: Trends Pharmacol. Sci. 20(8), 342-349 (1999).
28. Olesen OV, Linnet K: Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59(6), 298-309 (1999).
29. Matchar DB, Thakur, ME, Grossman I et al.: Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective seratonin reuptake inhibitors (SSRIs). Evidence Report/ Technology Assessment No. 122806, AHRQ Publication Rockville, MD: Agency for Healthcare Research and Quality (2007).
30. Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290(12), 1624-1632 (2003).
31. Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4), 291-302 (2006).
32. Murphy GM, Jr., Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF: Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry 61(11), 1163-1169 (2004).
33. Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R: Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 129(1), 36-40 (2004).
34. Kato M, Ikenaga Y, Wakeno M et al.: Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int. Clin. Psychopharmacol. 20(3), 151-156 (2005).
35. Kim DK, Lim SW, Lee S et al.: Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11(1), 215-219 (2000).
36. Pollock BG, Ferrell RE, Mulsant BH et al.: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23(5), 587-590 (2000).
37. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3(6), 508-511 (1998).
38. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH: Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry. 9(5), 433-441 (2004).
39. Yoshida K, Takahashi H, Higuchi H et al.: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am. J. Psychiatry. 161(9), 1575-1580 (2004).
40. Ham BJ, Lee MS, Lee HJ et al.: No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr. Genet. 15(4), 299-301 (2005).
41. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E: Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry 6(5), 586-592 (2001).
42. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP: Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry. 9(9), 879-889 (2004).
43. Serretti A, Artioli P: The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics. J. 4(4), 233-244 (2004).
44. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
45. Shah RR: Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos. Trans. R Soc. Lond. B Biol. Sci. 360(1460), 1617-1638 (2005).
46. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat. Rev. Drug Discov. 4(8), 639-647 (2005).
47. Kirchheiner J, Seeringer A: Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta 1770(3), 489-494 (2007).
48. van den Akker, van- Marle ME, Gurwitz D, Detmar SB et al.: Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7(5), 783-792 (2006).
49. Priest VL, Begg EJ, Gardiner SJ et al.: Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 24(8), 767-781 (2006).
50. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis. 43(1), 99-102 (2006).
51. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J. Acquir. Immune. Defic. Syndr. 45(1), 1-3 (2007).
52. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14(6), 335-342 (2004).
53. Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D: PREDICT-1 (CNA106030): the first powered prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm. Stat. (2007) (Epub ahead of print).
54. Marsh S, McLeod HL. Pharmacogenomics: from bedside to clinical practice. Hum. Mol. Genet. 15 Spec No 1, R89-R93 (2006).
55. Hillman MA, Wilke RA, Yale SH et al.: A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. 3(3), 137-145 (2005).
56. Roses AD: Pharmacogenetics in drug, development: Alzheimer's disease. Presented at: 11th International Congress of Human Genetics. Brisbane, Australia, August 6-10 (2006).
57. Singer C, Grossman I, Avidan N, Beckmann JS, Pe'er I: Trick or treat: the effect of placebo on the power of pharmacogenetic association studies. Hum. Genomics 2(1), 28-38 (2005).
58. Grossman I, Avidan N, Singer C et al.: Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet. Genomics 17(8), 657-666 (2007).
59. Lesko LJ, Woodcock J: Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat. Rev. Drug Discov. 3(9), 763-769 (2004).
60. Relling MV, Hoffman JM: Should pharmacogenomic studies be required for new drug approval? Clin. Pharmacol. Ther. 81(3), 425-428 (2007).
61. Burstein HJ: The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353(16), 1652-1654 (2005).
62. Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6(4), 287-293 (2007).
63. Gurwitz D, Lunshof JE, Dedoussis G et al.: Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical and health schools deans of education. Pharmacogenomics J. 5(4), 221-225 (2005).
64. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5(9), 645-656 (2004).
65. Shah RR: Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 7(6), 889-908 (2006).